Tenofovir Alafenamide

證據等級: L5

預測適應症: 3 個

TENOFOVIR ALAFENAMIDE: From HIV Infection to Simian Immunodeficiency Virus Infection

One-Sentence Summary

Tenofovir alafenamide (TAF) is a novel prodrug of tenofovir, established as a core component of antiretroviral therapy (ART) for HIV-1 infection and chronic hepatitis B in humans. The TxGNN model predicts it may be effective for Simian Immunodeficiency Virus (SIV) Infection, with 1 clinical trial (indirect, Phase 1/2) and 9 preclinical publications from macaque animal models currently supporting this direction.

Quick Overview

Item	Content
Original Indication	HIV-1 infection and chronic hepatitis B (core ART component)
Predicted New Indication	Simian Immunodeficiency Virus (SIV) Infection
TxGNN Prediction Score	99.89%
Evidence Level	L4 (preclinical animal studies only)
Taiwan Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

TAF is a prodrug of tenofovir that, following intracellular phosphorylation, generates tenofovir diphosphate — a potent inhibitor of viral reverse transcriptase (classified as a Nucleotide Reverse Transcriptase Inhibitor, NtRTI). This mechanism blocks the conversion of viral RNA into DNA, interrupting replication at a fundamental and conserved step across retroviruses.

SIV and HIV both belong to the primate lentivirus family (Lentivirus genus) and share highly homologous reverse transcriptase sequences. This structural conservation means TAF's inhibitory mechanism applies almost directly to SIV replication. In practice, macaque SIV/SHIV infection models serve as the gold-standard preclinical bridge for validating HIV antiretrovirals before human trials — TAF has been systematically deployed across these models to test oral PrEP regimens, long-acting formulations (implants, vaginal inserts), and early ART-driven remission strategies.

However, the practical repurposing value for human clinical application is limited: SIV infection primarily affects non-human primates in research and veterinary settings, not human patients. This prediction carries strong mechanistic plausibility and clear scientific utility in the preclinical/translational research context, but does not correspond to an unmet human clinical indication.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03577782	Phase 1/2	Unknown	12	Evaluated vedolizumab combined with ART (TAF used as ART backbone, not the primary investigational agent) in HIV-infected subjects for gut immune reconstitution and virological remission post-ART interruption. Indirect relevance: TAF's role is as background antiviral suppression, not the intervention under study. Trial ended at unknown status; enrollment too small for statistical conclusions.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
38134382	2024	Animal Study	J Infect Dis	TAF/EVG vaginal inserts provided 93–100% protection against repeated SHIV vaginal challenges in macaques when administered 4 hours before or after exposure, demonstrating strong extended post-exposure prophylaxis
39632836	2024	Animal Study	Nat Commun	Oral FTC/TAF combined with long-acting cabotegravir/rilpivirine achieved SHIV remission in macaques when treatment was initiated early; robust tissue reservoir penetration was highlighted as a key advantage of TAF
39559349	2024	Animal Study	Front Immunol	Humanized mouse model validated TAF-based ART efficacy against both SIV and HIV, supporting cross-species applicability for antiviral combination screening
35913838	2022	Animal Study	J Antimicrob Chemother	Biodegradable polycaprolactone implants releasing TAF protected macaques from vaginal SHIV infection, establishing proof-of-concept for long-acting sustained-release PrEP
31362305	2019	Animal Study	J Infect Dis	Oral TAF alone and TAF/FTC combination both prevented vaginal SHIV infection in macaques under repeated exposure; the TAF/FTC combination demonstrated superior protection rates
31730629	2019	Animal Study	PLoS One	Developed a reliable protocol for daily oral ART administration in macaques with high adherence rates, directly enabling reproducible TAF-based HIV/SIV prevention and treatment research
27465645	2016	Animal Study	J Infect Dis	Oral FTC/TAF protected macaques against rectal SHIV infection across 19 weekly exposures; TAF delivered substantially higher intracellular tenofovir diphosphate concentrations in lymphoid tissues compared to TDF
22740713	2012	Animal Study	J Infect Dis	Oral PrEP during acute SHIV infection in macaques significantly reduced systemic inflammation and CD4 T-cell loss compared to untreated infection, indicating immunological benefit beyond viral suppression
16810108	2006	Animal Study	J Acquir Immune Defic Syndr	Oral TDF and topical GS-7340 (early precursor to TAF) evaluated against repeated SIV oral challenges in infant macaques; demonstrated meaningful chemoprophylactic protection in a pediatric mother-to-infant transmission model

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: All current evidence for TAF in SIV infection derives from non-human primate preclinical models; no direct human clinical trials for this indication exist, and SIV infection is itself a non-human primate disease that does not represent an actionable unmet need in human medicine.

To proceed, the following is needed:

Clarify repurposing goal: If the intent is veterinary application (e.g., treating SIV in research colony animals or exploring cross-species lentiviral therapy), conduct species-specific pharmacokinetic and in vitro sensitivity studies for TAF against the relevant SIV strain
Expand to human-applicable lentiviral indications: If seeking a genuinely novel human indication within the lentivirus family, redirect investigation toward HTLV-associated conditions or other human retroviruses not currently covered by existing TAF approvals
Complete the safety profile: Obtain and parse the TFDA/AIFA package insert and DrugBank MOA data to resolve the current [Data Gap] in mechanism and warning information before any regulatory or clinical planning
Taiwan registration pathway: If any downstream human application is identified, an TFDA NDA/supplemental application strategy will be required given zero existing local authorizations
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.